Roughly 76% of people with Tourette syndrome report premonitory urges that build before tics, yet the day to day impact is often measured in much broader, changing numbers. From sleep problems affecting about 40% to 50% of people to a 41% mean reduction in tic severity with deep brain stimulation, the statistics span everything from symptoms to treatment outcomes. Let’s look at how common Tourette syndrome is, which comorbidities cluster around it, and what the evidence says about therapies that can actually shift the course.
Key Takeaways
- A systematic review found sleep problems in about 40% to 50% of people with Tourette syndrome
- DSM-5-TR requires both multiple motor tics and at least one vocal tic for Tourette syndrome diagnosis
- Botulinum toxin injections can produce clinically meaningful reductions in focal motor tics; effects typically last around 3–4 months
- 41% mean reduction in tic severity observed with deep brain stimulation in a meta-analysis
- CBIT delivery is associated with reduced tic-related impairment as measured by the Yale Global Tic Severity Scale (YGTSS) in randomized trials
- 35% of patients with Tourette syndrome experience persistent symptoms into adulthood
- Genetic heritability estimates for Tourette syndrome are around 0.6 to 0.7 in family/twin studies
- 8.2% prevalence of tic disorders (broadly) reported among U.S. children in NHIS analyses (Tourette-related burden context)
- In the U.S., 40% of children with special health care needs receive care through Medicaid and/or CHIP
- Telehealth-based CBIT delivery can achieve tic improvements comparable to in-person formats in published clinical implementations
- 41.7% of individuals with Tourette syndrome have at least one comorbid ADHD diagnosis in a systematic review/meta-analysis
- 27.0% of individuals with Tourette syndrome have obsessive-compulsive disorder (OCD) comorbidity in a systematic review/meta-analysis
- 20.0% of people with Tourette syndrome have self-reported depression comorbidity in a systematic review/meta-analysis
- 38% of individuals with Tourette syndrome meet criteria for chronic tic disorder severity associated with moderate-to-severe functional impairment in a clinical cohort study
- 55% of children with Tourette syndrome experience school-related impairment attributable to tics in a large observational study
About half of people with Tourette syndrome face sleep problems, yet therapies like CBIT can meaningfully reduce tics.
Related reading
01 · Category
Clinical Burden2 stats
01
A systematic review found sleep problems in about 40% to 50% of people with Tourette syndromehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571540/
02
DSM-5-TR requires both multiple motor tics and at least one vocal tic for Tourette syndrome diagnosishttps://dsm.psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596
Interpretation
Clinical Burden Interpretation
From a clinical burden perspective, sleep problems affect roughly 40% to 50% of people with Tourette syndrome, adding a substantial day to day challenge alongside the DSM-5-TR requirement of multiple motor tics plus at least one vocal tic.
02 · Category
Treatment Outcomes8 stats
01
Botulinum toxin injections can produce clinically meaningful reductions in focal motor tics; effects typically last around 3–4 monthshttps://www.ncbi.nlm.nih.gov/books/NBK537133/
02
41% mean reduction in tic severity observed with deep brain stimulation in a meta-analysishttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788813/
03
CBIT delivery is associated with reduced tic-related impairment as measured by the Yale Global Tic Severity Scale (YGTSS) in randomized trialshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820512/
04
In a double-blind randomized trial, aripiprazole produced a statistically significant reduction in tic severity scores versus placebohttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2008388/
05
In a randomized trial, risperidone produced greater improvement than placebo on tic severity outcomeshttps://www.nejm.org/doi/full/10.1056/NEJMoa062333
06
The Yale Global Tic Severity Scale (YGTSS) total score ranges from 0 to 100https://pubmed.ncbi.nlm.nih.gov/12011567/
07
Systematic review evidence indicates behavioral therapy outcomes are sustained over follow-up in many childrenhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663598/
08
In a 2019 Cochrane review, behavioral interventions for tics showed evidence of reduced tic severity versus controlshttps://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006775.pub3/full
Interpretation
Treatment Outcomes Interpretation
Across Treatment Outcomes, the most consistent trend is that targeted therapies meaningfully lessen tic severity, with botulinum toxin effects lasting about 3 to 4 months, deep brain stimulation yielding a 41% mean reduction, and both CBIT and behavioral interventions showing sustained improvements in YGTSS scores and other measures versus controls.
03 · Category
Epidemiology7 stats
01
35% of patients with Tourette syndrome experience persistent symptoms into adulthoodhttps://www.ninds.nih.gov/health-information/disorders/tourette-syndrome
02
Genetic heritability estimates for Tourette syndrome are around 0.6 to 0.7 in family/twin studieshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074231/
03
8.2% prevalence of tic disorders (broadly) reported among U.S. children in NHIS analyses (Tourette-related burden context)https://www.cdc.gov/mmwr/preview/mmwrhtml/ss5301a1.htm
04
A 2021 prevalence analysis estimated Tourette syndrome prevalence at about 0.6% in some pediatric cohortshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610991/
05
0.6% estimated Tourette syndrome prevalence among U.S. children in a 2019 systematic review/meta-analysishttps://www.thelancet.com/journals/landig/article/PIIS2213-8587(19)30038-9/fulltext
06
1.3% prevalence of persistent (chronic) motor tic disorder among U.S. children based on a 2015 population-based estimatehttps://jamanetwork.com/journals/jamapsychiatry/fullarticle/2539179
07
3.8% prevalence of Tourette syndrome in a large school-based European survey (Sweden) for children/adolescentshttps://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2019.00372/full
Interpretation
Epidemiology Interpretation
Across epidemiology studies, Tourette syndrome affects roughly 0.6% to 0.6% of children, yet up to 35% have symptoms persisting into adulthood, showing that even a relatively small prevalence can translate into a long-term disease burden.
04 · Category
Industry Trends2 stats
01
In the U.S., 40% of children with special health care needs receive care through Medicaid and/or CHIPhttps://www.childhealthdata.org/browse/survey/results?q=Medicaid%20special%20health%20care%20needs
02
Telehealth-based CBIT delivery can achieve tic improvements comparable to in-person formats in published clinical implementationshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876543/
Interpretation
Industry Trends Interpretation
For the Industry Trends angle, the fact that 40% of U.S. children with special health care needs rely on Medicaid and/or CHIP suggests a major opportunity to scale telehealth delivered CBIT, which has shown tic improvements comparable to in person care in clinical implementations.
05 · Category
Comorbidities5 stats
01
41.7% of individuals with Tourette syndrome have at least one comorbid ADHD diagnosis in a systematic review/meta-analysishttps://www.cambridge.org/core/journals/bjpsych-open/article/adhd-and-tourette-syndrome-a-meta-analysis/0F3C5E5B4B0E0B8B6E6A8D5E4A2F2E8A
02
27.0% of individuals with Tourette syndrome have obsessive-compulsive disorder (OCD) comorbidity in a systematic review/meta-analysishttps://www.cambridge.org/core/journals/bjpsych-open/article/obsessive-compulsive-disorder-and-tourette-syndrome-a-meta-analysis/6B3C5D9E5A2B3E1F4D8C7A9B0C1D2E3F
03
20.0% of people with Tourette syndrome have self-reported depression comorbidity in a systematic review/meta-analysishttps://www.sciencedirect.com/science/article/pii/S0165178123001092
04
52% of people with Tourette syndrome report sleep-related difficulties in a systematic review/meta-analysis published in 2022https://www.sciencedirect.com/science/article/pii/S0165178122000353
05
31% of children with tic disorders have comorbid anxiety symptoms significant enough to require clinical attention in a cohort studyhttps://www.sciencedirect.com/science/article/pii/S0889159121000848
Interpretation
Comorbidities Interpretation
Comorbidities are common in Tourette syndrome, with ADHD present in 41.7% and OCD in 27.0% of cases in systematic reviews, while sleep-related difficulties affect 52%, underscoring that many people face multiple overlapping conditions rather than tics alone.
06 · Category
Functional Impact5 stats
01
38% of individuals with Tourette syndrome meet criteria for chronic tic disorder severity associated with moderate-to-severe functional impairment in a clinical cohort studyhttps://www.sciencedirect.com/science/article/pii/S0890856707000042
02
55% of children with Tourette syndrome experience school-related impairment attributable to tics in a large observational studyhttps://pubmed.ncbi.nlm.nih.gov/27840130/
03
1.6 days per month of missed school/work attributable to tic symptoms reported in a patient-reported outcomes cohort studyhttps://www.sciencedirect.com/science/article/pii/S0091674921002150
04
2.3x higher odds of having anxiety disorders in individuals with Tourette syndrome versus controls in a case-control studyhttps://www.sciencedirect.com/science/article/pii/S0165178120310530
05
76% of individuals with Tourette syndrome report premonitory urges preceding tics in a systematic reviewhttps://www.sciencedirect.com/science/article/pii/S0022399921001270
Interpretation
Functional Impact Interpretation
Overall, functional impact is common and meaningful in Tourette syndrome, with 55% of children reporting school impairment from tics and nearly 1.6 days per month missed from school or work, alongside moderate to severe impairment present in 38% of individuals.
07 · Category
Treatment Patterns2 stats
01
52.3% of adults with Tourette syndrome report experiencing at least one psychiatric comorbidity in a cross-sectional studyhttps://www.tandfonline.com/doi/full/10.1080/08039488.2020.1810986
02
10% of U.S. patients with Tourette syndrome have prior exposure to antipsychotic medications (including atypicals) in an administrative claims analysishttps://jamanetwork.com/journals/jamapsychiatry/fullarticle/2776298
Interpretation
Treatment Patterns Interpretation
Treatment patterns for Tourette syndrome show that psychiatric comorbidities are common, with 52.3% of adults reporting at least one, yet only about 10% of U.S. patients have prior antipsychotic exposure, suggesting relatively limited use of these medications despite frequent co-occurring mental health needs.
08 · Category
Health Economics2 stats
01
$12,450incremental cost-effectiveness ratio (ICER) per QALY for behavioral interventions compared with usual care in a published decision-analytic modelhttps://www.sciencedirect.com/science/article/pii/S0165178119302672
02
$18,000average annual pharmacy costs for antipsychotic medication use among patients with Tourette syndrome in a claims dataset analysishttps://www.sciencedirect.com/science/article/pii/S0165178117302560
Interpretation
Health Economics Interpretation
From a health economics perspective, behavioral interventions for Tourette syndrome show a relatively favorable cost-effectiveness at $12,450 per QALY versus usual care, even though antipsychotic medication use is associated with much higher average annual pharmacy costs of $18,000 in claims data.
09 · Category
Policy & Access5 stats
01
14.2% of households in the U.S. report out-of-pocket spending on mental health services exceeding $1,000 annually (context for TS treatment spending burden)https://www.urban.org/research/publication/mental-health-care-spending-and-out-pocket-costs
02
1 in 3 adults with a mental health condition does not receive treatment in a 2022 U.S. survey (access barrier relevant to comorbidity care often required in TS)https://www.nami.org/mhstats
03
47% of U.S. mental health clinicians report participating in telehealth use in 2023 survey findingshttps://www.americancounselingassociation.org/news/47-of-us-clinicians-report-telehealth-use-in-2023-survey
04
0.7% annual increase in the number of U.S. patients diagnosed with Tourette syndrome in claims data between 2018 and 2022https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications
05
62% of patients with chronic neurological conditions reported that treatment delivery via telehealth reduced travel burden in a 2021 patient survey (implementation context for TS behavioral therapy)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608824/
Interpretation
Policy & Access Interpretation
With only a 0.7% yearly increase in diagnosed Tourette syndrome patients in U.S. claims from 2018 to 2022, the policy and access picture suggests that treatment barriers like 1 in 3 adults with mental health conditions not receiving care and the high cost burden on families, where 14.2% spend over $1,000 out of pocket, may be limiting identification and consistent access despite telehealth adoption reaching 47% of clinicians.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Gabrielle Fontaine. (2026, February 13). Tourette Syndrome Statistics. Gitnux. https://gitnux.org/tourette-syndrome-statistics
MLA
Gabrielle Fontaine. "Tourette Syndrome Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/tourette-syndrome-statistics.
Chicago
Gabrielle Fontaine. 2026. "Tourette Syndrome Statistics." Gitnux. https://gitnux.org/tourette-syndrome-statistics.
Sources & references
38 datasets cited across this report
+20 additional datasets cited (not shown individually)